The present invention provides oxaborole ester compounds and compositions thereof which are useful to treat diseases associated with parasites, such as Chagas Disease and African Animal Trypanosomosis.
Identification of a 4-fluorobenzyl l-valinate amide benzoxaborole (AN11736) as a potential development candidate for the treatment of Animal African Trypanosomiasis (AAT)
作者:Tsutomu Akama、Yong-Kang Zhang、Yvonne R. Freund、Pamela Berry、Joanne Lee、Eric E. Easom、Robert T. Jacobs、Jacob J. Plattner、Michael J. Witty、Rosemary Peter、Tim G. Rowan、Kirsten Gillingwater、Reto Brun、Bakela Nare、Luke Mercer、Musheng Xu、Jiangong Wang、Hao Liang
DOI:10.1016/j.bmcl.2017.11.028
日期:2018.1
Novel L-valinate amide benzoxaboroles and analogues were designed and synthesized for a structure-activity-relationship (SAR) investigation to optimize the growth inhibitory activity against Trypanosoma congolense (T. congolense) and Trypanosoma vivax (T. vivax) parasites. The study identified 4-fluorobenzyl (1-hydroxy-7-methyl-1,3-dihydrobenzo[c][1,2] oxaborole-6-carbonyl)-L-valinate (5, AN11736), which showed IC50 values of 0.15 nM against T. congolense and 1.3 nM against T. vivax, and demonstrated 100% efficacy with a single dose of 10 mg/kg against both T. congolense and T. vivax in mouse models of infection (IP dosing) and in the target animal, cattle, dosed intramuscularly. AN11736 has been advanced to early development studies. (C) 2017 The Authors. Published by Elsevier Ltd.
L-VALINATE AMIDE BENZOXABOROLE DERIVATIVES FOR THE TREATMENT OF PARASITIC DISEASES
申请人:Anacor Pharmaceuticals, Inc
公开号:EP3578562B1
公开(公告)日:2021-06-23
OXABOROLE ESTERS AND USES THEREOF
申请人:Anacor Pharmaceuticals, Inc.
公开号:US20170327519A1
公开(公告)日:2017-11-16
The present invention provides oxaborole ester compounds and compositions thereof which are useful to treat diseases associated with parasites, such as Chagas Disease and African Animal Trypanosomosis.